Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Voyager Therapeutics (VYGR) Shares Outstanding (2016 - 2025)

Voyager Therapeutics' Shares Outstanding history spans 11 years, with the latest figure at $59.0 million for Q4 2025.

  • For Q4 2025, Shares Outstanding rose 7.89% year-over-year to $59.0 million; the TTM value through Dec 2025 reached $59.0 million, up 7.89%, while the annual FY2025 figure was $59.0 million, 7.89% up from the prior year.
  • Shares Outstanding for Q4 2025 was $59.0 million at Voyager Therapeutics, up from $55.5 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $59.0 million in Q4 2025 and bottomed at $37.6 million in Q1 2021.
  • The 5-year median for Shares Outstanding is $43.8 million (2023), against an average of $46.2 million.
  • The largest annual shift saw Shares Outstanding grew 1.39% in 2021 before it increased 25.05% in 2024.
  • A 5-year view of Shares Outstanding shows it stood at $37.9 million in 2021, then grew by 1.83% to $38.6 million in 2022, then grew by 14.05% to $44.0 million in 2023, then grew by 24.28% to $54.7 million in 2024, then increased by 7.89% to $59.0 million in 2025.
  • Per Business Quant, the three most recent readings for VYGR's Shares Outstanding are $59.0 million (Q4 2025), $55.5 million (Q3 2025), and $55.4 million (Q2 2025).